Knights of Columbus Asset Advisors LLC Has $6.19 Million Holdings in Stryker Corporation $SYK

Knights of Columbus Asset Advisors LLC lessened its position in shares of Stryker Corporation (NYSE:SYK) by 27.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 17,612 shares of the medical technology company’s stock after selling 6,598 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $6,190,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SYK. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter valued at approximately $27,000. CGC Financial Services LLC acquired a new stake in Stryker during the 4th quarter valued at approximately $29,000. Strive Asset Management LLC acquired a new stake in Stryker during the 3rd quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker during the 3rd quarter valued at approximately $34,000. Finally, Ares Financial Consulting LLC acquired a new stake in Stryker during the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $306.16 on Thursday. The stock has a market capitalization of $117.37 billion, a price-to-earnings ratio of 35.44, a PEG ratio of 1.97 and a beta of 0.80. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The stock’s 50 day moving average price is $323.45 and its two-hundred day moving average price is $348.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent analyst reports. William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. BTIG Research decreased their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Leerink Partners initiated coverage on shares of Stryker in a research report on Monday, April 13th. They set an “outperform” rating and a $410.00 target price for the company. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. cut their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.